Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01993004 · ClinicalTrials.gov registry record
Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells
A clinical trial, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- 24
- Enrollment target
NCT01993004: Completed study, sponsored by Rutgers, The State University of New Jersey.
NCT01993004 is a clinical trial that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01993004 has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- 24 participants
- Enrollment target
Study Summary
MicroRNAs regulate gene expression. The abnormal expression of microRNAs has been reported in many human diseases. The purpose of this pilot study is to determine if microRNA expression is changed in untreated and glatiramer acetate-treated patients with multiple sclerosis.
Primary Outcome
Expression of multiple microRNA is being tested in B cells in three groups of subjects at one time point
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-07 |
| Est. Completion | 2015-12 |
What the finished NCT01993004 record still lists
NCT01993004 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 24 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01993004 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01993004 about?
NCT01993004 is a clinical study titled "Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells". MicroRNAs regulate gene expression. The abnormal expression of microRNAs has been reported in many human diseases. The purpose of this pilot study is to determine if microRNA expression is changed in untreated and glatiramer acetate-treated patients with multiple sclerosis.
What is the current status of trial NCT01993004?
This trial is currently completed. The enrollment target is 24 participants. The study started on 2013-07. Estimated completion is 2015-12.
Who is sponsoring clinical trial NCT01993004?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia